PharmaMar has requested the process of re-examination for Aplidin® from

(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.

PharmaMar has requested the process of re-examination for Aplidin® from the EMA

Related Posts

Survival Outcomes Linked to Timing of Immune Checkpoint Inhibitor Dosing

Factors Influencing Elderly Preference for Dental Services

Frequency-Dependent Deep Brain Stimulation in Motor Thalamus Alters Speech and Swallowing

Neonatal Monocyte Iron Handling Drives Immunometabolic Responses in Sepsis

POPULAR NEWS

Groundbreaking Discovery: New Shark Species Identified for the First Time

Controlled Study Defines Pediatric Long COVID Features

Behavioral Nudge Boosts Medication Prescriptions for Alcohol Reduction

Clean Cooking and Remittances Slash Somalia’s Ecological Footprints

About

Follow us

Recent News

Survival Outcomes Linked to Timing of Immune Checkpoint Inhibitor Dosing

Factors Influencing Elderly Preference for Dental Services

Frequency-Dependent Deep Brain Stimulation in Motor Thalamus Alters Speech and Swallowing

Subscribe to Blog via Email

Welcome Back!

Retrieve your password